Medical Pharmacology: Immunopharmacology (Immunosuppressants/Immunomodulators) Practice Questions
Attribution: Petkova, Elena &
Yordanova, Vanya & Staevska, Maria & Valerieva, Anna. (2022).
Safety Aspects and Rational Use of Lanadelumab Injections in the
Treatment of Hereditary Angioedema (HAE): Clinical Insights.
Drug, Healthcare and Patient Safety. Volume 14. 195-210.
10.2147/DHPS.S345443.
Lanadelumab (Takhzyro): Treatment
of Hereditary Angioedema
Click on the correct answer.
Lanadelumab (Takhzyro):
Human monoclonal antibody
Prevents angioedema in those with hereditary angioedema.
Both
Neither
Lanadelumab (Takhzyro): First monoclonal antibody (United States) for prophylactic treatment preventing hereditary angioedema episodes
True
False
Lanadelumab (Takhzyro):
Binds to plasma kallikrein, inhibiting proteolytic activity.
Appropriate for use in patients older than 12 years of age.
Both
Neither
In patients with hereditary angioedema (HAE), plasma kallikrein concentrations are not regulated because of the absence of C1-inhibitor.
True
False
Plasma kallikrein enzymic activity (proteolytic) cleaves kininogen leading to elevated bradykinin levels that cause swelling and pain in patients with HAE.
True
False
Lanadelumab (Takhzyro) side effect/effects
Injection site reactions
Upper respiratory infections
Myalgia
A & B
B & C
A & C
A, B & C
Lanadelumab (Takhzyro):
Mechanism of action is inhibition of plasma kallikrein.
Hereditary angioedema occurs due to deficiencies/dysfunctionality of C1 inhibitor, an enzyme regulating the kallikrein-kinin cascade.
Both
Neither
Drug/drugs useful in providing long-term prophylaxis against angioedema include lanadelumab, berotralstat (kallikrein inhibitor), androgens (limited use), tranexamic acid (limited use).
Rothlin C Gutkind J Chapter 39
Immunosuppressants, Immunomodulation and Tolerance In
Goodman & Gilman's The Pharmacological Basis of Therapeutics
(Brunton LL Knollman BC eds) McGraw Hill LLC (2023).
Lake D & Briggs A Ch 55 Immunopharmacology
in Katzung's Basic & Clinical Pharmacology (Vanderah TW, ed)
16e McGraw Hill 2023.
Chrouos G Ch 39 Adrenocorticosteroids &
Adrenocortical Antagonists in Katzung's Basic & Clinical
Pharmacology (Vanderah TW, ed) 16e McGraw Hill 2023
Brezinski E Klickstein L Armstrong A Ch 46
Pharmacology of Immunosuppression in Principles of
Pharmacology: The Pathophysiologic Basis of Drug Therapy.
(Golan DE Armstrong EJ Armstrong AW, eds) 4e
2017
Ritter JM Flower R Henderson G Loke YK
MacEwan D Robinson E Fullerton J Ch 25 Anti-inflammatory and
Immunosuppressant Drugs Rang & Dale's Pharmacology 10e
Elsevier 2024.
Burchum J Rosenthal L Lehne's Pharmacology
for Nursing Care Ch 72 Immunosuppressants Elsevier 2022.
Burchum J Rosenthal L Lehne's Pharmacology
for Nursing Care Ch 75 Glucocorticoids in Nonendrocrine
Disorders Elsevier 2022.
Burchum J Rosenthal L Lehne's Pharmacology
for Nursing Care Ch 76 Drug Therapy for Rheumatoid Arthritis
Elsevier 2022.
Bass A Rogatsky Ch 32 Immunomodulatory Drugs
in Goldman-Cecil Medicine (Goldman L Schafer, eds) Elsevier
26e 2020
Leiva M Takemoto Ch 238 Immunosuppressants in
Lippincott Illustrated Reviews: Pharmacology 8e ((Walen et
al, eds) Wolters Kluwer 2023.
Hall J Hall M Ch 78 Adrenocortical
Hormones Guyton and Hall Textbook of Medical Physiology 14e
Elsevier 2021.
Waller DG Sampson A Hitchings Ch 38 The
Immune Response and Immunosuppressant Drugs
Medical Pharmacology & Therapeutics 6e Elsevier 2022
Waller DG Sampson A Hitchings Ch 30
Rheumotoid Arthritis, Other Inflammatory Arthrides and
Osteoarthritis Medical Pharmacology & Therapeutics 6e
Elsevier 2022
